We detected and quantified tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6) from monocytes/ macrophages (M+) in the peripheral blood of subjects from three different population groups, i.e., tuberculin-negative healthy subjects, tuberculin-positive healthy subjects, and patients with active pulmonary tuberculosis. TNF-a or IL-6 activity in the culture supernatant of these cells was determined by the cytotoxicity of murine L-929 cells or by enzyme-linked immunosorbent assay, respectively. Detection and enumeration of cells secreting either TNF-e or IL-6 were performed by an adaptation of the enzyme-linked immunospot assay.
Cellular immune reaction plays an important role in tuberculous infection, a chronic granulomatous disease. When cellular immunity develops, a large number of activated macrophages (MO~) are accumulated in the tuberculous foci because of the chemotactic effect of certain lymphokines, and these M4X actively phagocytize and suppress the multiplication of tubercle bacilli (12) . On the other hand, many MX are killed during the process of phagocytosis, thus releasing large amounts of lysosomal enzymes, superoxide and hydrogen peroxide, neutral proteases, and cytotoxic substances such as tumor necrosis factor (TNF), which may cause tissue damage, e.g., caseous necrosis and softening and liquefaction, followed by cavity formation (4) .
M( can be activated in the inflammatory processes in response to infection with Mycobacterium tuberculosis and other related Mycobacterium species, and they synthesize and release various cytokines, including interleukin-1 (IL-1), TNF, interferon, IL-6, and IL-8 (1, 2, 9, 16). These cytokines are regarded as inflammatory mediators, and they may be important modulators of local and systemic biological responses. Mycobacterial proteins, in addition to live organisms, have been reported to induce IL-1 and TNF in monocytes/M4l (17, 20) . However, no attempts to measure actual numbers of cells producing these cytokines with reference to the status of mycobacterial infections have been made. In this report, we demonstrate the presence of increased amounts of TNF-a and IL-6 in monocytes/M4X from the peripheral blood of subjects infected with tuberculous bacilli by using a newly developed method.
MATERIALS AND METHODS
Reagents. Muramyl dipeptide (MDP) was kindly supplied by Daiichi Seiyaku Co., Ltd., Tokyo, Japan. Lipopolysaccharide (LPS) from Escherichia coli O55:B5 was a product * Corresponding author.
of List Biological Laboratories, Campbell, Calif. Human recombinant TNF-a (rTNF-a; specific activity, 3 x 106 U/mg) was a generous gift from Dainippon Pharmaceutical Co., Osaka, Japan. Human recombinant IL-6 (rIL-6; specific activity, 107 U/mg) and mouse anti-IL-6 monoclonal antibody were kindly provided by T. Kishimoto and T. Hirano, Institute for Molecular and Cellular Biology, Osaka University, Suita, Osaka, Japan.
Subjects. Three population groups were sampled; these groups included a tuberculosis group composed of 12 patients with recently diagnosed pulmonary tuberculosis, a healthy control group composed of 13 normal subjects with a positive tuberculin test, and another healthy control group composed of 11 normal subjects with a negative tuberculin test. The tuberculin test was done by intradermal injection of 0.05 p,g of purified protein derivative (Nippon BCG Products Co. Ltd., Tokyo, Japan) into these subjects. The positive tuberculin test was defined as appearance of induration with a diameter of .10 mm 48 h after injection of purified protein derivative. The patients with tuberculosis were diagnosed on the basis of an abnormal chest X-ray radiograph, positive cultivation of M. tuberculosis from sputum, and febrile responses. They had been treated with drug regimens including streptomycin, isoniazid, ethambutol, or rifampin for ca. 50 days, and they showed no significant febrile responses when their blood samples were taken. The characteristics of the three experimental groups of subjects are summarized in Table 1 IL-6 assay. The IL-6 assay was an enzyme-linked immunosorbent assay (ELISA) (19) . Briefly, 96-well ELISA plates (M129; Dynatech Laboratories Ltd., Billingshurst, United Kingdom) were coated with 100 pl of monoclonal antibody specific for IL-6 (1 pig/ml) at 4°C overnight in 0.1 M carbonate buffer (pH 9.6). The wells were then blocked with 100 ,u of 1% bovine serum albumin-phosphate-buffered saline (PBS) at 4°C overnight and washed with PBS containing 0.05% Tween 20 (PBS-T). Test samples were added to each well. After overnight incubation at 4°C, the wells were washed with PBS-T, and rabbit anti-IL-6 antibodies (10 ng in 100 pAl of PBS; Genzyme Corp., Boston, Mass.) biotinylated with NHS-X-Biotin (Pierce, Rockford, Ill.) were added. The plates were incubated at 4°C overnight and washed with PBS-T. Next, ABC-AP kit reagent (alkaline phosphatase standard AK-5000, Vector Laboratories, Burlingame, Calif.) was added to each well, and the A405 was read with a Titertek Multiskan MC photometer. Values obtained from triplicate wells were averaged to obtain the mean values and their standard errors. IL-6 titers in culture supernatants were determined with a standard IL-6 curve under the assay conditions described above, and titers were expressed as the mean number of IL-6 units + standard error of each subject Individual wells were coated with monoclonal anti-TNF-a or anti-IL-6 antibody and incubated with MNL for 24 h at 37°C in a humidified atmosphere of 5% CO2 in air. After being washed with PBS-T to remove the cells, the plates were incubated with biotinylated anti-TNF-a or anti-IL-6. Spots were developed with avidinperoxidase by using 3-amino-9-ethylcarbazole as the substrate.
twofold, and an equal volume of diluted mouse monoclonal antibody to human rTNF-a (clone E43; Olympus Immunochemicals, Tokyo, Japan), which neutralized TNF-a activity of 107 U/ml, or rabbit anti-rIL-6 antibody (Genzyme), which completely neutralized 10,000 U of human rIL-6 per ml, was added to each diluent. The mixtures were incubated at 37°C for 2 h before being assayed for TNF-a or IL-6 activity as described above.
ELISPOT assay for cytokine-secreting cells. An adaptation of the enzyme-linked immunospot (ELISPOT) assay originally developed by Czerkinsky et al. (8) was used to enumerate TNF-a-or IL-6-specific spot-forming cells (SFC) as outlined in Fig. 1 Statistics. Comparisons between groups were done by Student's t test for independent samples.
RESULTS
The specificity of antibodies to TNF-a and IL-6 was demonstrated by the neutralization of TNF-a and IL-6 activity in the culture supernatant of LPS-or MDP-stimulated peripheral blood monocytes/M4. The activity of these cytokines was found to be almost completely neutralized by rabbit anti-human rTNF-a or rabbit anti-human rIL-6 antibody, respectively (Fig. 2) .
We then developed a sensitive and specific system for the detection of individual cytokine-producing human cells which secrete either TNF-a or IL-6. The specificity of the spot developed was confirmed as follows. Active secretion specific for TNF-a in the ELISPOT assay was demonstrated by the addition of cycloheximide (25 jig/ml), which reduced the number of SFC by 70 to 95%. Preincubation of rabbit anti-TNF-a or anti-IL-6 antibody with the MNL culture before addition of biotinylated antibody specific for either cytokine in the ELISPOT assay reduced the development of spots by 75 to 97%, whereas normal rabbit immunoglobulin G had no effect (data not shown). Figure 3 shows that LPS-or MDP-stimulated monocytes/MX from patients with pulmonary tuberculosis and tuberculin-positive healthy subjects released higher levels of TNF-ot and IL-6 than those from tuberculin-negative healthy subjects. No significant levels of TNF-a or IL-6 activity were detected in the culture supernatant of unstimulated monocytes/M4) from either tuberculin-positive or tuberculinnegative subjects. Furthermore, the monocytes/M40 from patients with tuberculosis produced more TNF-a and IL-6 than those from tuberculin-positive healthy subjects. Maximum TNF-a and IL-6 activity occurred at LPS and MDP concentrations of 10 and 100 ,ug, respectively.
Activated monocytes/M( from tuberculin-positive subjects with LPS or MDP induced higher numbers of cytokinesecreting cells than inactivated controls in all population groups (Fig. 4) . The number of SFC that produced cytokines in either LPS-or MDP-stimulated MNL from tuberculinpositive healthy subjects and patients with tuberculosis was 3,300 to 3,600 TNF-a-specific SFC per 106 MNL and 4,100 to 4,600 IL-6-specific SFC per 106 MNL. However, no significant difference in the number of cytokine-secreting cells from patients with tuberculosis and tuberculin-positive (c), and tuberculin-negative healthy subjects (0). The amounts of cytokines produced were determined by TNF-a or IL-6 assay, respectively. Values (mean + standard error) are expressed as units per milliter of culture supernatant. Symbols: * and **, statistical difference from the value for the tuberculin-negative subject group with or without stimulation of LPS or MDP at P < 0.05 and P < 0.01, respectively.
healthy subjects was noted. In contrast, the numbers of TNF-a-and IL-6-secreting SFC in MNL from tuberculinnegative healthy subjects were markedly lower than the numbers of these SFC in MNL from tuberculin-positive healthy subjects (Fig. 4) .
DISCUSSION
We have clearly demonstrated here that the monocytes/M4) of tuberculin-positive subjects produced enhanced levels of TNF-a and IL-6 when stimulated with either MDP or LPS. On the other hand, monocytes/M4X from tuberculinnegative healthy subjects released TNF-a but not IL-6 upon stimulation by LPS or MDP. We also found that not only E. coli LPS but also synthetic lipid A and its analogs stimulated human monocytes/M4) of tuberculin-positive and -negative subjects to exhibit TNF-a activity (data not shown). It is of interest to note that both MDP and LPS are parts of bacterial cell structural components and that infection with M. tuberculosis appears to enhance the ability of monocytes/M4) to synthesize certain cytokines such as TNF-a and IL-6. In this regard, Klimpel et al. (10) have recently reported that fibroblasts infected with bacteria such as Shigella, Salmonella, or Listeria spp. exhibited enhanced susceptibility to the cytotoxic activity of TNF-a.
Production of TNF-a and IL-6 in LPS-or MDP-stimulated monocytes/Mo from tuberculin-positive subjects, including patients with active tuberculosis, was shown to be significantly enhanced (Fig. 3) . It patients with newly diagnosed tuberculosis was significantly higher than that in tuberculin-negative donors, whereas in patients with chronic refractory tuberculosis it was depressed (15) . It is also true that TNF was directly induced in peripheral blood monocytes and alveolar MX in tuberculinnegative subjects by mycobacterial whole cells and their cell preparations (17) . Wallis et al. (20) showed that two protein fractions of M. tuberculosis with molecular weights of 46,000 and 20,000 directly induced IL-1 and TNF production by blood mononuclear cells in tuberculin-negative donors.
In addition to the higher amounts of TNF-a produced, we have found higher IL-6 production in monocytes/MX from tuberculin-positive healthy subjects than in those from tuberculin-negative healthy subjects (Fig. 3) . It is reasonable to hypothesize that cytokine production is enhanced in the peripheral blood cells and in body fluids, such as pleural fluid, of patients with tuberculosis. In fact, gamma interferon, as well as TNF, was produced in greater amounts in tuberculous patients than in healthy subjects, and greater amounts of both were found in the pleural fluid than in the blood of patients with tuberculous pleuritis (3, 13) .
It was shown that the number of TNF-a-and IL-6-specific SFC in MNL of tuberculin-positive subjects was markedly higher than their number in the MNL of tuberculin-negative healthy subjects (Fig. 4) . LPS (and to a lesser extent MDP) stimulation of MNL from tuberculin-positive subjects did enhance the number of SFC-secreting TNF-aL and IL-6 (Fig.  4) . It is suggested that the cytokine-secreting cells in patients infected with M. tuberculosis or in healthy subjects immunized with M. bovis BCG are activated in vitro by LPS or MDP, resulting in increases not only in the amounts of products secreted from the cytokine-secreting cells but also in the number of such cells. Thus, the results ( Fig. 3 and 4 ) obtained in this study clearly show the correlation between frequencies of cytokine-secreting cells and levels of cytokine production upon stimulation with either LPS or MDP within the three subject groups. It may be speculated that mycobacterial infection in the lung sensitize monocytes/M( locally to produce TNF-a upon priming with LPS or MDP or that TNF-ot is produced and concentrated at the sites of tuberculous lesions. The TNF-a thus synthesized may play a role in human antimycobacterial defenses (3). IL-6 production by monocytes/M4 from patients with tuberculosis or tuberculin-positive healthy subjects is of interest. Enhanced production of IL-6 may be implicated in localized proliferative diseases (18) . Further, these cytokines may trigger an autoamplification process that results in higher cytokine production, contributing to granuloma formation and defense against local invasion by pathogens (3). It should be mentioned here that methods of enumerating TNF-a-, gamma interferon-, and IL-18-secreting cells in mouse and human lymphoid organs have been developed recently by Skidmore et al. (14) and Czerkinsky et al. (7) .
